Tennessee Center for Clinical Trials is a dedicated clinical research facility located in Tullahoma, TN. We specialize in Cardiovascular, Metabolic / Endocrinology research. We have supported enrollment across over 166,117 clinical trial participants. Our experienced team is dedicated to delivering high-quality clinical research and exceptional patient care.
A randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy of budesonide, glycopyrronium, and formoterol fumarate metered-dose inhaler relative to glycopyrronium and formoterol fumarate MDI on cardiopulmonary outcomes in chronic obstructive pulmonary disease.
A Phase III, randomized, double-blind study to evaluate the effect of balcinrenone/dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired kidney function.
A multicenter, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. Protocol CYI033.
oA Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of maridebart cafraglutide on mortality and morbidity in participants living with obesity and heart failure.
A double-blind, randomized, placebo-controlled, multicenter study assessing olpasiran use to prevent first major cardiovascular events in participants with elevated lipoprotein(a).
A Phase III, randomized, double-blind, placebo-controlled, parallel-group study to assess the effect of AZD0780 on major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk for a first ASCVD event.
A Phase III, randomized, open-label, blinded-endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficient participants with symptomatic chronic heart failure.
oA master protocol for a Phase 3, multicenter, randomized study to evaluate the efficacy and safety of REGN7508 and REGN9933, monoclonal antibodies against factor XI, in participants with recent lower-extremity revascularization for symptomatic peripheral artery disease.
A master protocol for a Phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with REGN7508 and REGN9933, monoclonal antibodies against factor XI, versus placebo in participants with atrial fibrillation for whom oral anticoagulation is unsuitable.
A Phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with REGN7508, a monoclonal antibody against FXI, versus apixaban in participants with atrial fibrillation.